{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&q=PD-L1", "query": { "q": "PD-L1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&q=PD-L1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:34:57.625Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06524544", "title": "A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2025-12-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 159, "location_summary": "Phoenix, Arizona • Irvine, California • Orange, California + 125 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06524544" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 18, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab 400 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab placebo (saline)", "type": "DRUG" }, { "name": "Olaparib 300 mg BID", "type": "DRUG" }, { "name": "Olaparib matching placebo", "type": "DRUG" }, { "name": "Etoposide 100 mg/m^2", "type": "DRUG" }, { "name": "Platinum, investigator's choice", "type": "DRUG" }, { "name": "Standard Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Prophylactic Cranial Irradiation (PCI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 672, "start_date": "2020-12-08", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 35, "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624204" }, { "nct_id": "NCT02803333", "title": "Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "No Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-02-16", "completion_date": "2021-11-19", "has_results": false, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02803333" }, { "nct_id": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Mismatch Repair Deficiency", "Refractory Colorectal Carcinoma", "Refractory Lung Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-02", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983578" }, { "nct_id": "NCT05216835", "title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Sabestomig (AZD7789)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "16 Years to 101 Years" }, "enrollment_count": 45, "start_date": "2022-03-18", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216835" }, { "nct_id": "NCT06974734", "title": "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non Small Cell Lung", "Carcinoma, Pancreatic Ductal", "Malignant Melanoma", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "PF-08046037", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2025-05-06", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 14, "location_summary": "Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974734" }, { "nct_id": "NCT03059147", "title": "Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "SF1126", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SignalRX Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2017-03-27", "completion_date": "2020-06-29", "has_results": false, "last_update_posted_date": "2022-05-18", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059147" }, { "nct_id": "NCT02841748", "title": "A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2017-05-10", "completion_date": "2025-10-23", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02841748" }, { "nct_id": "NCT03225664", "title": "Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-24T10:34:57.625Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03225664" } ] }